Why the Ecofibre (ASX:EOF) share price is soaring 9% higher today

The Ecofibre Ltd (ASX: EOF) share price is soaring 9% higher during mid-morning trade after providing an interim investor update. We take a closer look.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Ecofibre Ltd (ASX: EOF) share price is on the move during mid-morning trade after providing an interim investor update.

At the time of writing, the hemp company's shares are swapping hands for as much as 86.5 cents apiece, up 9.4%.

What did Ecofibre announce?

Investors are fighting to get a hold of Ecofibre shares following the company's strong recovery of business growth.

In a statement to the ASX, Ecofibre revealed improved momentum in its core United States independent pharmacy business. In April alone, the Ananda Professional pharmacy segment saw its best month since September 2020.

As a result, the company reaffirmed its profit guidance released in February for the FY21 period.

Ecofibre expects profit to come at a loss of $1.5 million for the second half of the year. This will contribute to an overall forecasted loss of around $7 million for FY21.

Pleasingly, the H2 FY21 profit is looking to include roughly US$1.8 million from employee retention credits. The funds to be received fall under former President Trump's 'Taxpayer Certainty and Disaster Tax Relief Act of 2020'. This was a coronavirus relief and spending bill to assist businesses that were forced to close during the government-mandated lockdown.

Ecofibre CEO, Eric Wang touched on the company's progress saying:

Since the middle of March, we have seen a good return to growth in our core independent pharmacy channel as COVID related disruptions subside.

We see trading conditions improving for our core independent pharmacy channel as the US moves into post-COVID environment. We look forward to Ananda Health revenues returning to pre-COVID levels in due course.

Ecofibre share price snapshot

While today's positive announcement lifted Ecofibre shares, yearly performance has not been so kind to investors. The company's share price has fallen more than 70% from the past 12 months and is down almost 60% year-to-date.

Ecofibre has a market capitalisation of approximately $271 million, with about 339.3 million shares on issue.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.
Healthcare Shares

Regis Healthcare acquires Royal Freemasons' Victorian home care business

Regis Healthcare has announced the acquisition of Royal Freemasons’ home care business, expanding its client base and annualised home care…

Read more »

Two researchers discussing results of a study with each other.
Healthcare Shares

CSL vs Telix shares: Which is the better buy?

One valuation immediately caught my attention, while the other requires considerably more confidence in future growth.

Read more »

A healthcare worker wearing a white coat holds his fingers to his mouth looking worried as healthcare stocks like Cochlear crash today
Healthcare Shares

This ASX healthcare stock trades at its cheapest multiple in a decade

A quality business at a decade-low multiple. What gives?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Healthcare Shares

CSL shares bounced in July after a brutal year: What's next?

Can CSL sustain July's rebound when it reports FY2026 results this month.

Read more »

Three businesswomen collaborate around a table.
Healthcare Shares

Clarity Pharmaceuticals reports clinical progress in June 2026 quarter

Clarity Pharmaceuticals reported $178.3 million in cash and strong clinical progress for the June 2026 quarter.

Read more »

A male doctor and a woman in scrubs in the foreground smile.
Healthcare Shares

Mesoblast FY26 earnings: Ryoncil revenue up, new trial milestones for ASX:MSB

Mesoblast reported a strong full year with US$115 million in Ryoncil revenue and advanced key clinical trials for future growth.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

CSL launches clinical trials for new plasma manufacturing process

CSL will launch clinical trials of its new Horizon 2 plasma process in 2027, seeking enhanced yields and regulatory approvals.

Read more »

A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

Should I buy CSL shares before the end of July?

Here's what I expect from the beaten-down biotech stock next month.

Read more »